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Background: Human interactome is predicted to contain 150,000 to 300,000 protein-protein interactions, (PPIs).
Protein-fragment complementation assay (PCA) is one of the most widely used methods to detect PPI, as well as
Förster resonance energy transfer (FRET). To date, successful applications of firefly luciferase (Fluc)-based PCA have
been reported in vivo, in cultured cells and in cell-free lysate, owing to its high sensitivity, high signal-to
-background (S/B) ratio, and reversible response. Here we show the assay also works with purified proteins with
unexpectedly rapid kinetics.
Results: Split Fluc fragments both fused with a rapamycin-dependently interacting protein pair were made and
expressed in E. coli system, and purified to homogeneity. When the proteins were used for PCA to detect
rapamycin-dependent PPI, they enabled a rapid detection (~1 s) of PPI with high S/B ratio. When Fn7-8 domains
(7 nm in length) that was shown to abrogate GFP mutant-based FRET was inserted between split Fluc and FKBP12
as a rigid linker, it still showed some response, suggesting less limitation in interacting partner’s size. Finally,
the stability of the probe was investigated. Preincubation of the probes at 37 degreeC up to 1 h showed marked
decrease of the luminescent signal to 1.5%, showing the limited stability of this system.
Conclusion: Fluc PCA using purified components will enable a rapid and handy detection of PPIs with high S/B
ratio, avoiding the effects of concomitant components. Although the system might not be suitable for large-scale
screening due to its limited stability, it can detect an interaction over larger distance than by FRET. This would be
the first demonstration of Fluc PCA in vitro, which has a distinct advantage over other PPI assays. Our system
enables detection of direct PPIs without risk of perturbation by PPI mediators in the complex cellular milieu.
Keywords: Protein-protein interaction, Firefly luciferase, Bioluminescence, Protein fragment complementation assay,
Thermostability, In vitro diagnosticsBackground
It is estimated that there are about 150,000 to 300,000
protein-protein interactions (PPI) in human interactome
[1,2]. In order to discover and investigate PPI, explor-
ation of PPI assays is considered highly important.
Among various PPI assays, protein-fragment comple-
mentation assay (PCA) is a simple and user-friendly* Correspondence: ueda@res.titech.ac.jp
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distribution, and reproduction in any mediummethod [3]. In PCA, a reporter protein, such as a green
fluorescent protein (GFP) variant [4,5] and a luciferase
[6-10] is dissected to a split from, and each split reporter
protein is fused to an interacting partner (Figure 1).
While the split reporter proteins have low reporter activ-
ity when they exist far apart (Figure 1A), they reconsti-
tute and recover the activity when the proteins come
close due to the association of interacting partner
(Figure 1B). In general, due to its low background activ-
ity, PCA displays high signal to background ratio (S/B).
Especially, bioluminescence-based PCAs such as split-
luciferase reporters shows reversible property [11], in
contrast to the irreversible nature of the reassembled
GFP-like fluorescent proteins [5]. In addition, sinceMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Figure 1 Principle of Fluc PCA (A) Fluc is dissected into two parts, N-terminal domain and C-terminal domain. Each fragment is fused to
one of interacting partners, respectively. When interacting partners are far apart, luminescence is not observed. (B) When PPI occurs, the two Fluc domains
come close. (C) Upon reconstitution, the luminescence is markedly increased. (D) When the PPI inhibitor is added, the luminescence is diminished.
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for their detection, the assay enables noninvasive and
sensitive optical imaging in living cells and animals.
While PPI is conveniently assayed by PCA in vivo and
in cultured cells, it is often desirable to be performed
also in vitro, to know whether the interaction is direct or
not, since many PPI mediators, inhibitors and enhancers
may exist in the complex cellular milieu. To date, Porter et
al. successfully utilized a cell-free transcription/translation
system for performing firefly luciferase (Fluc)-based PCA
in vitro [11]. Their probes can be prepared in shorter time
period than the probes expressed in E. coli, yeast or mam-
malian cells. However, the assay needs expensive cell-free
lysate, and whose components always have a risk to affect
PPI. Here we report a PCA using purified interacting
proteins fused with split Fluc proteins, to detect PPI in
a defined solution. We also examined the stability of
the probes, and the detectable distance between the
interacting partners. To the best of our knowledge, this
will be the first investigation of pure in vitro PPI, based on
Fluc PCA.
Results
For the PPI to be investigated, we first selected a well-
known interacting domain pair of FKBP12 and FRB.
FKBP12 is a 12 kD domain of FK506 binding protein
(FKBP), which is able to associate with FKBP-rapamycin
-associated protein (FRB) depending on an antibiotic,
rapamycin (PPI mediator in Figure 1) [12,13]. To this
end, FKBP12 or FRB gene was fused to the 50 of Fluc N-
terminal (1–437 in amino acid, aa) or C-terminal do-
main (394–547 in aa) gene, yielding four types of fusion
protein genes (FKBP/N, FKBP/C, FRB/N, and FRB/C).
The genes were inserted to pET32b vector, and the
thioredoxin-fused proteins were expressed in the soluble
fraction of E. coli BL21(DE3, pLysS) and purified by animmobilized metal affinity chromatography (Figure 2A).
The two interacting pairs (FKBP/N - FRB/C and FKBP/
C - FRB/N) were mixed at 50 nM each, and equimolar
rapamycin was added to the mixtures. Just after adding
the two substrates ATP and luciferin, the luminescent
intensity was measured by a luminometer at 0.1 s inter-
vals for 4 s. As a result, the intensity of the interacting
pairs added with rapamycin showed a marked increase.
In contrast, the pairs without rapamycin displayed very
low luminescence (Figure 2B). In addition, non-interacting
protein pairs (FKBP/N - FKBP/C, and FRB/N - FRB/C), as
well as each fusion protein alone exhibit very low lumines-
cence even in the presence of rapamycin (Figure 2C). The
results clearly showed that the PPI can be specifically
detected with high S/B ratio using purified probes.
To assess the degree of spontaneous Fluc reconstitution,
the assay with one of the best interacting pairs FRB/N and
FKBP/C was performed at several probe concentrations
(Figure 3). At all the concentrations tested, the lumines-
cent signals increased rapamycin-dependently (Figure 3,
A-D). The resulting maximum signal/background (S/B)
ratio increased to as high as 130 when at the probe con-
centration increased up to 250 nM, while the ratio at 750
nM was slightly lower (Figure 3E). This was possibly
because the high probe concentration rather promoted
spontaneous Fluc reconstitution without rapamycin.
When the rapamycin dose–response at 50 nM probe con-
centration was examined, the limit of detection was deter-
mined as 250 pM (Figure 3F).
For Fluc PCA, several successful split sites are reported
to date. To investigate on this issue, another pair of
N-terminal domain (1–398) together with the same C-
terminal domain (394–547) was employed according
to a previous attempt that gave good response in vivo
(Additional file 1: Figure S1) [14]. We could express
and purify the new N-domain similarly (Additional file 1:
BC
A
Figure 2 Fluc PCA using purified probes (A) Purification of the Fluc PCA probes. Lane 1, FKBP/N; Lane 2, FRB/N; Lane 3, FKBP/C; Lane 4,
FRB/C. (B) PCA using the purified probes at 50 nM each, with/without equimolar rapamycin (Rap). Average and SD values of three samples are




Figure 3 Concentration dependency of Fluc PCA and sensitivity to rapamycin (A-D) Fluc PCA with FRB/N and FKBP/C with/without
equimolar rapamycin at indicated concentrations. Average and SD of three samples are shown. (E) Concentration dependency of signal/background
ratio. (F) Rapamycin dose–response using 50 nM each probes. ** : Limit of detection showing higher signal-1SD than the background signal +2SD.
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signals at several concentrations of FRB/N(1–398) –
FKBP/C pair (Additional file 1: Figure S1, B-E). However,
compared with the FRB/N(1–437) – FKBP/C(394–547)
pair, the signal intensity was lower, and the resultant S/B
ratio was rather unstable, albeit not low (Additional file 1:
Figure S1F). This was probably because of the instability
of the N-domain (1–398), which is reflected to its degra-
dation products observed in Additional file 1: Figure S1A.
Since rapamycin-dependent FKBP-FRB interaction is
one of very strong protein-protein interactions [15], an-
other cellular interaction of Mdm2 and p53 was investi-
gated (Figure 4). Mdm2 oncoprotein is a cellular inhibitor
of the p53 tumor suppressor in that it can bind the trans-
activation domain of p53 and down-regulates its ability to
activate transcription. In certain cancers, mdm2 amplifica-
tion is a common event and contributes to the inactiva-
tion of p53 [16]. The probes fused to the trans-activation
domain of p53 and Mdm2 (p53/C, p53/N, Mdm2/C and
Mdm2/N) were constructed in the same way as FKBP/C
and FRB/N (1–437) (Figure 4A). This time, both the signal
intensity and S/B ratio elevated depending on the concen-
tration of the probes (Figure 4, B-F). Then we investigated
whether the in vitro Fluc PCA could detect the reversibil-
ity of interaction. After we mixed the probes p53/C andA
B C
E F
Figure 4 Detection of p53 - Mdm2 interaction (A) SDS-PAGE of p53 a
Mdm2/N; Lane 4, Mdm2/C. (B-E) Fluc PCA using an interacting partner p53
N (dark cyan) each at indicated concentrations. Average and SD of three sa
C and Mdm2/N. (G) Effect of Nutlin-3 on p53-Mdm2 interaction. Average aMdm2/N at 100 nM each, Nutlin-3, a known inhibitor of
p53-Mdm2 interaction, was added and measured for the
Fluc activity (Figure 4G). The result clearly showed a
Nutlin-3 concentration dependent luminescence inhibi-
tion with calculated IC50 of 368 ± 25 nM. Although the
value is higher than the reported one (90 nM) [17], this
might be due to the racemization of Nutlin-3 used. Taken
together, these results clearly showed the generality of the
assay to detect PPIs including transient interactions.
Due to the nature of split enzyme, we reasoned that
the instability of the purified probes could be a possible
demerit of Fluc-based PCA. To examine the stability of
the probes, the mixtures of 100 nM FKBP/C and 100
nM FRB/N with or without equimolar rapamycin were
incubated at 37°C for 0–60 min, and applied to the lumi-
nescence assay (Additional file 2: Figure S2). As a result,
the incubation resulted in a time-dependent decrease in
luminescent intensity of the pair added with rapamycin
(Additional file 2: Figure S2A). As short as 15 min incu-
bation resulted in the activity loss to less than one-third
of that before incubation. The longer incubation for
60 min resulted in virtually no signal difference between
the pairs with and without rapamycin (Additional file 2:
Figure S2, B and C). These results clearly indicate that
the Fluc PCA probes have a limited stability in thisD
G
nd Mdm2 fusion probes. Lane 1, p53/N; Lane 2, p53/C; Lane 3,
/C and Mdm2/N (orange) or a non-interacting partner p53/C and p53/
mples are shown. (F) Signal/background ratios of Fluc PCA using p53/
nd SD of three samples are shown.
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their limited stability in vivo or in lysate, which is prob-
ably sequestered by the newly synthesized probes.
Förster resonance energy transfer (FRET) is an excel-
lent PPI detection method both in vitro and in vivo, and
regarded as a standard tool in this area [18]. However,
FRET has a fundamental limitation that it only occurs
over rather short distance of several nm between the donor
and the acceptor fluorophores, depending on Förster dis-
tance R0, which is determined a priori by the dye combi-
nation used [19,20]. Therefore, the interaction between
proteins with large dimensions is a challenging task for
FRET, due to the possible long distance between the at-
tached dyes including fluorescent proteins. To compare
Fluc PCA with FRET, we examined the effect of distance
between interacting partners. Previously, we introduced
several helix-forming peptide linkers with various lengths
between EGFP and EBFP, and those linkers showed the
ability to control the distance between interacting partners
[21]. According to this, a similar helix-forming linker, 4-
repeats of Asp-Asp-Ala-Lys-Lys (4 ×DDAKK), was inserted
between FKBP12 and Fluc C-terminal domain. The SDS
polyacrylamide gel electrophoresis of the fusion proteins
(Figure 5A) suggests effective separation of FKBP12 and
Fluc C-terminal domain by the inserted linkers. Using 100
nM each mixture of FKBP/4 ×DDAKK/C, FRB/N and
rapamycin, PPI was detected with a high S/B ratio with a
slight reduction compared with the pairs without helical
linkers (Figure 5B). In addition, when a linker with 7 re-
peats of Asp-Asp-Ala-Lys-Lys (7 ×DDAKK) was inserted
between FKBP12 and Fluc C-terminal domain, high S/B
ratio was still maintained (Figure 5, A and C).
For a further examination, the 7th and 8th domains of
fibronectin type III (Fn7-8) with a 7 nm N-C terminal
distance was inserted between FKBP12 and Fluc C-





Figure 5 Insertion of helix linkers (A) SDS-PAGE of the probes inserte
Lane 3, FKBP/ 7 × DDAKK /C. (B) PCA using the probe with 4 × DDAKK. The
(n = 3). (C) PCA using the probe with 7 × DDAKK. The condition is the sameof purified proteins, while the mobility of the reporter
was lowered by the insertion of Fn7-8, no significant re-
duction in the yield and purity was observed (Figure 6A,
Lanes 1 and 4). Ohashi et al. reported that the insertion
of Fn7-8 domains between the fluorescent protein pair
CyPet and Ypet results in barely detectable FRET signal.
[22]. To confirm this, Fn7-8 was inserted between
FKBP12 and a brighter CFP variant Cerulean (FKBP/Fn7-
8/Cerulean) (Figure 6A, Lanes 2 and 3). As expected, very
weak FRET signal derived of FKBP/Fn7-8/Cerulean and
FRB-fused Ypet (FRB/Ypet) was observed, although a dis-
tinct FRET-derived peak was observed for the construct
without Fn7-8 insertion (Figure 6B).
On the other hand, the PCA pair of FKBP/Fn7-8/C
and FRB/N at 750 nM displayed a moderate but signifi-
cant S/B ratio, clearly showing its superiority over FRET,
although the observed rapamycin dependency was not
so clear when reduced amounts (100 nM) of the probes
were used (Figure 6C). Nevertheless, the Fluc PCA sys-
tem was shown to work for detecting PPI over longer
distance, which was not detectable by FRET.
Discussion
Previously, Fluc-based PCA has been utilized as a sensi-
tive tool to investigate PPI in vivo and in cultured cells.
However, considering possible disturbance by the co-
existing components acting as PPI mediators, enhancers
and inhibitors, PPI assay in vitro will also give us invalu-
able information. Furthermore, the in vitro assay has the
possibility to study PPIs between pathogen-derived cyto-
toxic proteins and host proteins, which are normally im-
possible to perform in vivo. In this study, we showed
that Fluc PCA also works with purified elements. The
system displayed high S/B ratio and unexpectedly rapid
response (~1 s). In PCA, the background signal due to
nonspecific activation of the reporter can be a problem. AsC
KK/C  FKBP/7  DDAKK/C  
          &  
      FRB/N
d with helix linkers. Lane 1, FKBP/C; Lane 2, FKBP / 4 × DDAKK /C;




Figure 6 Comparison with FRET in the presence of a rigid linker (A) SDS-PAGE of the PCA/FRET probes with or without Fn7-8 domains.
Lane 1, FKBP/Fn7-8/C; Lane 2, FRB/Ypet; Lane 3, FKBP/Cerulean; Lane 4 FKBP/Fn7-8/Cerulean. (B) FRET assays. Left: the assay using the probe pair
without insertion. Right: the assay using the probe pair inserted with Fn7-8. (C) Fluc PCA using the probe inserted with Fn7-8. The probe/
rapamycin concentrations of 750 nM (left) and 100 nM (right) were investigated (n = 3).
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pairs were slightly higher than those of single probe alone,
probably reflecting the nonspecific reconstitution of split
Fluc. However, when the specific PPI was induced by
rapamycin, it resulted in markedly higher signal, giving
high S/B ratio. Therefore, in practice the nonspecific sig-
nals hardly interfere with the PPI detection (Figure 2).
The only but not easily avoidable drawback of this
system is the instability of probe as shown in Additional
file 2: Figure S2. Apparently, the system is not very suit-
able for large-scale screening that needs longer sample
preparation time. However, proper cooling of the re-
agents and samples during the preparation period will
surely reduce such inactivation. Therefore, we think
that the system has a potential for low-cost and high-
throughput drug screenings. On the other hand, a dis-
tinct merit of this system is robustness to the interaction
detection over longer distance. In fact, insertion of either
long helical linker or a rigid large protein domain didnot deteriorate PPI detection, while FRET signal was
barely detectable when Fn7-8 was inserted (Figure 6B).
These results show a lesser limitation in distance be-
tween interacting partners in PCA than in FRET. There-
fore, this system will be available for the interactions
between large proteins that cannot be assayed by FRET.
While the reason for observed nonspecific PPI signal re-
mains unclear, it may be due to the interaction between
the inserted sequence and the other probe. In addition,
we could observe the higher S/B ratio with the higher
concentration of a probe set (Figure 6C). Use of higher
probe concentration is desirable to assay larger interacting
partners. The nearly straight shape of the kinetic curve
observed might reflect the large dimension of Fn7-8,
which would lower the reconstitution efficiency and sub-
sequent luminescent reaction rate.
Collectively, considering the demerits and the merits,
Fluc PCA using purified elements enables us a rapid and
convenient detection of direct PPI with high confidence.
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The feasibility of Fluc PCA in vitro using purified ele-
ments was demonstrated for the first time. The assay
was found to have high S/B ratio, and allow the detec-
tion of larger size of interacting partner than detectable
by FRET. In spite of relatively weak thermostability, the
assay will be applicable to handy detection of various




ATP and D-luciferin (LH2) were from Sigma, St. Louis,
MO. MOPS (3-(N-morpholino)propanesulfonic acid) was
from Dojindo, Kumamoto, Japan. Rapamycin was from
Wako Pure Chemical Industries, Osaka, Japan or LKT La-
boratories, St. Paul, MN. Synthetic genes for E. coli codon-
optimized human FKBP12, appended with Nco I / Sfi I
and NotI sites at the 5’ and 30 ends, respectively, were from
Mr Gene GmbH, Regensburg, Germany. The plasmid
pFH154 encoding human fibronectin cDNA was from
Health Science Research Resources Bank (HSRRB), Osaka,
Japan. Other reagents in the highest grade available were
from Wako Pure Chemical Industries unless otherwise
indicated.
Construction of FKBP/FRB fused Fluc fragments
The DNA fragment encoding Fluc was obtained by PCR
using pGEX-Ppy vector [23] as a template, and primers
LucNotG4SB (50- gg cgc gcc GCG GCC GCC GGT GGT
GGT GGT AGC ATG GAA GAC GCC AAA AAC ATA
AAG-30) encoding a G4S linker and NotI site (underlined)
and LucXhoF (50- g gcg cgc CTC GAG CTT TCC GCC
CTT CTT GGC CT- 30) containing XhoI site (underlined).
Similarly, N- and C-terminal domain genes were amplified
with primers LucNotG4SB and Luc437XhoF (50-g gcg cgc
CTC GAG GCG GTC AAC TAT GAA GAA GTG- 30),
and Luc394NotG4SB (50- gg cgc gcc GCG GCC GCC
GGT GGT GGT GGT AGC GGA CCT ATG ATT ATG
TCC GG-30) and LucXhoF, respectively. The amplified
fragments were cloned into pET32b (Merck, Darmstadt,
Germany) between the NotI and XhoI sites, to give pET32/
Fluc, pET32/FlucN and pET32/FlucC, respectively. The
synthetic genes encoding FKBP12 and FRB cDNAs were
digested with NcoI and NotI, and the digested fragments
inserted in pET32/FlucN and pET32/FlucC digested with
the same enzymes each other, to give pET32/FKBP/FlucN,
pET32/FKBP/FlucC, pET32/FRB/FlucN and pET32/FRB/
FlucC.
Construction of FRB fused FlucN(1–398) fragments
The DNA fragment encoding Fluc N-terminal domain
(1–398) was obtained by PCR using pET32/FRB/FlucN as
a template, and primers LucNotG4SB and Luc398XhoF(50- t gtt tac ata CTC GAG cat aat cat agg tcc tct tac- 30)
containing XhoI site (underlined). The amplified frag-
ments were cloned into pET32/FRB/FlucN between the
NotI and XhoI sites, to give pET32/FRB/FlucN (1–398).
Construction of p53/Mdm2 fused Fluc fragments
The DNA fragment encoding transactivation domain of
p53 (residue 15–29) and two restriction sites (underlined)
was obtained by thermal cycling using following oligonu-
cleotides: p53NcoBack (50-gg aat tCC ATG GCT AGT
CAG GAA ACA TTT TCA GAC CTA TGG AAA C-30)
and p53NotFor (50- g gga ttc tGC GGC CGC GTT TTC
AGG AAG TAG TTT CCA TAG GTC TG-30). Mdm2
gene (residue 17–125) was obtained by PCR with human
Mdm2 gene as a template and mdm2NocBack (50-gg aat
tCC ATG GCT TCG GAA CAA GAG ACC C-30) and
mdm2NotFor (50-g gaa ttc tGC GGC CGC CTG CTG
ATT GAC TAC TAC C-30) as primers. The amplified frag-
ments were digested with NcoI and NotI, and inserted to
pET32/FKBP/FlucC and pET32/FRB/FlucN digested with
the same enzymes, to give pET32/p53/FlucN, pET32/p53/
FlucC, pET32/Mdm2/FlucN and pET32/Mdm2/FlucC.
Insertion of 4 × DDAKK between FKBP12 and FlucC
The two oligonucleotides DDAKK4_NotBack2 (50 –g gaa
ttc GCG GCC GCA GAT GAT GCT AAA AAA GAT
GCT AAA AAA GAT GAT GCC AAG AAG GAC GAC
GC- 30) containing NotI site (underlined), and DDAKK4_
EagFor2 (50 –g gaa ttC GGC CGA TTT TTT AGC ATC
ATC TTT TTT CGC GTC GTC CTT CTT GGC- 30)
containing EagI site (underlined) were annealed and ex-
tended using a thermal cycler. The fragment was digested
with EagI, and inserted into pET32/FKBP/FlucC digested
with NotI, to give pET32/FKBP/4 × DDAKK/FlucC.
Insertion of 7×DDAKK between FKBP12 and FlucC
pET32/FKBP/4 × DDAKK/FlucC was amplified with the
primers, DDAKK_VectorNotB (50-GA CGA CGC CAA
AAA AGA TGA TGC CAA GAA GG-30), and DDAKK_
VectorNotF (50-CT TTT TTA GCATCATCT GCG G-30).
The 4 ×DDAKK fragment inserted in pET32/FKBP/4 ×
DDAKK/FlucC was amplified with the primers DDAKK_
LinkerB (50 –GA TGA TGC TAA AAA AGA TG- 30) and
DDAKK_LinkerF (50-TT TTT TGG CGT CGT CTT TTT
TCG CGT CGT C- 30). The two amplified fragments were
connected using In-Fusion HD cloning kit (Takara-Bio,
Shiga, Japan), to obtain pET32/FKBP/8 ×DDAKK/FlucC,
which resulted in unexpected acquisition of pET32/FKBP/
7 ×DDAKK/FlucC.
Construction of FKBP/FRB fused with fluorescent proteins
The cDNAs for Ypet on pYpet-His (kindly provided by Dr.
PS Daugherty) [24] and Cerulean [25] made from pEBFP-
N1 plasmid (Clontech, Takara-Bio) were amplified using
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XhoI sites, digested with NotI and XhoI, and inserted into
pET32/FKBP/FlucN and pET32/FRB/FlucN digested with
the same enzymes, to give pET32/FKBP/Cerulean and
pET32/FRB/Ypet.
Insertion of Fn7-8 as a rigid linker
The sequence for Fn7-8 was amplified from human fibro-
nectin cDNA with the primers Fn7EagBack (50-g gaa ttC
GGC CGC ACC ATT GTC TCC ACC AAC AAA C- 30)
and Fn8EagFor (50-g gaa ttC GGC CGA TGT TTT CTG
TCT TCC TCTAAG- 30) each containing an EagI site. The
amplified fragment was digested with EagI, and was in-
serted into pET32/FKBP/FlucC and pET32/FKBP/Cerulean
digested with same enzyme, respectively.
Expression and purification of probe proteins
All the fusion proteins were expressed in E. coli BL21
(pLysS, DE3) (Novagen) as a thioredoxin and hexahistidine-
tagged protein. To purify the expressed fusion proteins,
Talon metal affinity resin (Clontech) was used according to
the manufacturer’s instruction. Concentration of the puri-
fied protein was determined by CBB-stained SDS-PAGE
co-loaded with various concentrations of BSA as a concen-
tration standard. The protein added with final 15 % glycerol
was stored at −80°C before use.
Detection of PCA
The purified probe proteins with or without rapamycin
were suspended in 100 mM MOPS, 10 mM MgSO4,
pH 7.3. The mixture (50 μl each) was dispensed to a well
of 96-well half well white plate (Corning-Costar, NY, USA).
The light intensity was measured immediately after injec-
tion of 50 μl 2 × substrate solution (40 mM ATP and
150 μM LH2 in 100 mM MOPS, 10 mM MgSO4, pH 7.3)
with a periodical integration for 0.1 s using a luminometer
Phelios AB-2350 (ATTO, Tokyo, Japan).
FRET assay
Fluorescence spectra were measured by F-2500 fluores-
cence spectrophotometer (Hitachi High-Technologies,
Tokyo, Japan). Samples were diluted in 250 μl PBS, pH 7.4.
The mixture of FKBP/cerulean or FKBP/Fn/cerulean and
FRB/Ypet (40 nM each) was excited at 433 nm, and the
fluorescent spectra at 455–600 nm were recorded in the
presence and absence of 40 nM rapamycin.
Additional files
Additional file 1: Figure S1. Fluc PCA using a probe split at different
site FRB/N (1-398). (A) SDS-PAGE of purified FRB/N (1-398). (B-E) Fluc PCA
using FRB/N (1-398) and FKBP/C in 15, 50, 150, and 450 nM. (F) Signal/
background ratios of Fluc PCA using FRB/N (1-398) and FKBP/C.Additional file 2: Figure S2. Examination of the probe stability. After
incubating 100 nM each of the probes with equimolar rapamycin (A) or
without rapamycin (B) for 0 (lemon), 15 (yellow), 30 (orange) and 60 min
(red) at 37°C, PCA was performed as before. In (B), smaller scale of the
vertical axis is used in the inset. (C) Comparison of the luminescent
intensities with/without rapamycin after 60 min incubation.
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FKBP: FK506 binding protein; Fluc: firefly luciferase; Fn7-8: 7–8 domains of
fibronectin type III; FRB: FKBP-rapamycin-associated protein;
FRET: fluorescence resonance energy transfer; GFP: green fluorescent protein;
MOPS: 3-(N-morpholino)propanesulfonic acid; PCA: protein-fragment
complementation assay; PPI: protein-protein interaction.
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